Bioisosterism in Drug Design: Classical & Non-Classical Bioisosteres

Added:

Limitations of Empirical Bioisosterism and the Challenge of Activity Cliffs

While bioisosterism is a foundational strategy in medicinal chemistry, critics highlight its reliance on empirical heuristics, which can be highly unpredictable. A primary challenge is the phenomenon of 'activity cliffs,' where minor, supposedly bioisosteric replacements (like replacing a hydrogen with a fluorine or methyl group) result in drastic, non-linear losses in potency or unexpected toxicity. This occurs because traditional bioisosteric classifications often oversimplify the complex, three-dimensional electronic and conformational demands of target binding sites. Consequently, modern drug discovery increasingly favors computational de novo design, machine learning, and fragment-based drug discovery (FBDD). These approaches bypass rigid, historical bioisosteric rules to map and optimize ligand-protein interactions directly. By exploring entirely novel chemical spaces rather than relying on incremental scaffold-hopping, computational methods address the limitations of empirical bioisosterism, providing a more precise, target-centric alternative to traditional drug design.

Fundamental principles of organic chemistry, specifically functional groups, hybridization, and steric/electronic molecular properties.
The concept of Structure-Activity Relationships (SAR) and how chemical modifications affect a molecule's biological activity.
Basic understanding of drug-receptor interactions, including intermolecular forces like hydrogen bonding, electrostatic, and hydrophobic interactions.
The historical concept of chemical isosterism, including Irving Langmuir's definition and Grimm's Hydride Displacement Law.
Advanced lead optimization strategies in medicinal chemistry to improve ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles.
The role of bioisosterism in avoiding patent infringement and establishing new 'me-too' drugs in the pharmaceutical market.
Design of peptidomimetics, substituting unstable peptide bonds with stable bioisosteric groups to improve oral bioavailability.
Application of Computer-Aided Drug Design (CADD) and bioisosteric replacement databases for virtual screening.
1K views21likes24:45@RFQ-09-18Original Release: 2025-03-20

Bioisosterism is a fundamental concept in medicinal chemistry where small structural modifications to drug molecules can significantly enhance their therapeutic properties by replacing functional groups with bioisosteric equivalents that maintain similar molecular shape, electronic distribution, and physicochemical properties while improving drug stability, potency, selectivity, and safety; this approach is classified into classical bioisosteres (which strictly follow steric and electronic definitions) and non-classical bioisosteres (which may share only partial characteristics), with real-world applications demonstrated in FDA-approved drugs such as 5-fluorouracil (uracil → fluorine), 6-mercaptopurine (hydroxyl → sulfur), losartan (carboxylic acid → tetrazole), and aspirin (salicylic acid → acetylsalicylic acid).